Venus Remedies Quarterly Results for Trading Insights
In Sept 2025, Venus Remedies (VENUSREM) reported revenue ₹195 Cr and net profit ₹20 Cr — revenue +9.6% YoY. Compare with VENUSREM fundamental valuation to assess whether the stock is under or overvalued.
VENUSREM Quarterly Results — Revenue, Profit & EPS Highlights
Venus Remedies latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Venus Remedies screener.
- Revenue of ₹195 Cr in Sept 2025 (-3.5% vs Mar 2025, +9.6% vs Sept 2024)
- Net Profit of ₹20 Cr in Sept 2025 (-4.8% vs Mar 2025, +400.0% vs Sept 2024)
- EBITDA of ₹33 Cr in Sept 2025 (-8.3% vs Mar 2025)
- Operating Margin of 16.0% in Sept 2025 (+1.0pp vs Mar 2025)
- Earnings Per Share of ₹15.06 in Sept 2025 (-4.1% vs Mar 2025)
Venus Remedies Quarterly Results — Revenue, EBITDA, Net Profit & EPS
VENUSREM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 195 | 202 | 141 | 183 | 178 | -3.5% | 9.6% |
| Net Profit (₹ Cr) | 20 | 21 | 10 | 26 | 4 | - | - |
| EBITDA (₹ Cr) | 33 | 36 | 19 | 40 | 16 | - | - |
| EPS (₹) | 15.06 | 15.71 | 7.18 | 19.14 | 2.63 | - | - |
| Operating Margin (%) | 16.0% | 15.0% | 11.0% | 21.0% | 4.0% | - | - |
VENUSREM Share Price Trend — 1-Year Movement Across Quarterly Results
Venus Remedies 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore VENUSREM share price data to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
VENUSREM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Venus Remedies latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1891.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 145.5 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6858.0 | 2,860 | 689 | +7.1% | - | 24.1% | 264.1 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹148,702.77 Cr | 4469.2 | 3,219 | 591 | +11.3% | - | 18.4% | 254.8 |
|
Cipla
Mar 2026 |
₹115,205.68 Cr | 1401.9 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 204.1 |
|
Dr Reddys Laborator…
Mar 2026 |
₹111,107.68 Cr | 1318.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.5 |
All amounts in ₹ Crores